Avalo Therapeutics (AVTX)
NASDAQ:AVTX
Holding AVTX?
Track your performance easily

Avalo Therapeutics (AVTX) Financial Statements

873 Followers

Avalo Therapeutics Financial Overview

Avalo Therapeutics's market cap is currently ―. The company's EPS TTM is $-192.227; its P/E ratio is -0.05; Avalo Therapeutics is scheduled to report earnings on November 6, 2024, and the estimated EPS forecast is $-1.45. See an overview of income statement, balance sheet, and cash flow financials.
Jun 24Mar 24Dec 23Sep 23Jun 23
Income Statement-
Total Revenue---$ 236.00K$ 643.00K
Gross Profit$ -343.00K$ 80.00K-$ -11.00K$ -65.00K
EBIT$ 98.47M$ -5.23M$ -8.18M$ -5.22M$ -8.19M
EBITDA$ 98.50M$ -5.20M$ -8.13M$ -4.05M$ -7.80M
Net Income Common Stockholders$ 98.46M$ -121.29M-$ -5.23M$ -8.19M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 93.43M$ 110.18M-$ 10.20M$ 6.32M
Total Assets$ 108.31M$ 119.96M-$ 29.27M$ 24.23M
Total Debt$ 0.00$ 0.00$ 0.00$ 0.00$ 14.12M
Net Debt$ -93.43M$ -110.18M$ 0.00$ -10.20M$ 7.80M
Total Liabilities$ 110.46M$ 236.27M-$ 14.57M$ 31.20M
Stockholders Equity$ -13.61M$ -112.54M-$ 14.70M$ -6.97M
Cash Flow-
Free Cash Flow$ -16.30M$ -6.20M$ -2.80M$ -6.80M$ -10.98M
Operating Cash Flow$ -16.30M$ -6.20M-$ -6.80M$ -10.98M
Investing Cash Flow-$ 356.00K---
Financing Cash Flow$ -472.00K$ 108.61M-$ 10.70M$ 598.00K
Currency in USD

Avalo Therapeutics Earnings and Revenue History

Avalo Therapeutics Debt to Assets

Avalo Therapeutics Cash Flow

Avalo Therapeutics Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis